Use of idarucizumab in clinical practice: a case report
Authors:
Libuše Husová
Authors place of work:
Centrum kardiovaskulární a transplantační chirurgie, Brno
Published in the journal:
Vnitř Lék 2019; 65(5): 377-378
Category:
Case reports
Summary
Budd-Chiari syndrome is a serious condition which in chronic course leads to the development of liver cirrhosis. Anticoagulant treatment of this syndrome is fully indicated and in the treatment can be used dabigatran. Advanced cirrhosis of the liver due to this disease can be an indication for a liver transplant. In this case, it is a great advantage the existence of an antidote to dabigatran (idarucizumab) in order to adjust the coagulation ratios and prevent bleeding disorders. Referred to a case report describes the first experience with idarucizumab in context with liver transplant in a patient with Budd-Chiari syndrome
Keywords:
antidote – bleeding – dabigatran – direct oral anticoagulants (DOAC) – idarucizumab – liver transplant
Zdroje
- Šembera Š, Hůlek P. Onemocnění jaterních cév. In: Hůlek P, Urbánek P et al. Hepatologie. 3. vydání. Grada: Praha 2018. ISBN 437–451.978–80–271–0394–2.
- Warfarin. Souhrn údajů o přípravku. Informace z WWW: http://www.sukl.cz.
- Kvasnička J, Penka M, Kvasnička T et al. Doporučení České společnosti pro trombózu a hemostázu J. E. Purkyně pro bezpečnou léčbu novými antikoagulancii (NOAC) – dabigatran etexilátem, apixabanem a rivaroxabanem. Vnitř Lék 2015; 61(6): 537–546.
- Pradaxa. Souhrn údajů o přípravku. Informace z WWW: http://www.sukl.cz.
- Pollack CV, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373(6): 511–520. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1502000>.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2019 Číslo 5
Najčítanejšie v tomto čísle
- Communication with cancer patient
- Surgical treatment of chronic thromboembolic pulmonary hypertension
- Limited ambulatory night sleep testing in patients with a suspicion of sleep apnoea syndrome: Is its indication tenable?
- Nontuberculous mycobacterial disease: a case report-based review